AIM ImmunoTech Inc. (AIM)
Upgrades & Downgrades
Latest AIM news
AIM ImmunoTech ends 2Q well-positioned to achieve multiple clinical and regulatory milestones
15 August 2022
AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter financial results that showed ample cash on hand, giving the company scope to achieve multiple clinical and regulatory milestones. The Florida-based...
Aimia, Inc. (AIMFF) CEO Philip Mittleman on Q2 2022 Results - Earnings Call Transcript
12 August 2022
Aimia, Inc. (OTCPK:AIMFF) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Steven Leonard - CFO Philip Mittleman - CEO & Director Michael Lehmann - President & Director...
AIM ImmunoTech reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long ...
28 July 2022
AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating its investigational drug Ampligen as a therape...
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
14 July 2022
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July ...
AIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in ...
21 June 2022
AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at...
AIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen an...
13 June 2022
AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent - covering Ampligen (rintatolimod) and other dsRNA ...
AIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVID
18 May 2022
AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its long COVID investigat...
AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies
21 April 2022
AIM ImmunoTech Inc (NYSE:AIM) has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. In ...
AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study
12 April 2022
AIM ImmunoTech Inc (NYSE:AIM). has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270...
AIM ImmunoTech reports positive data from Phase 2a study evaluating Ampligen as part of a regimen tr...
11 April 2022
AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as a...